<DOC>
	<DOCNO>NCT00405496</DOCNO>
	<brief_summary>The purpose phase 2 study determine difluprednate ophthalmic emulsion effective treatment uveitis .</brief_summary>
	<brief_title>Study Difluprednate Ophthalmic Emulsion Treatment Uveitis</brief_title>
	<detailed_description>The primary objective investigate efficacy safety 0.05 % difluprednate ophthalmic emulsion patient endogenous anterior uveitis determine clinical usefulness treatment disease early phase development , comparison Rinderon® solution ( contain 0.1 % betamethasone sodium phosphate ) widely use treatment postoperative inflammation , uveitis , etc . steroid ophthalmic solution . The secondary objective establish evaluation system dose-finding study .</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Uveitis , Anterior</mesh_term>
	<mesh_term>Iridocyclitis</mesh_term>
	<mesh_term>Difluprednate</mesh_term>
	<mesh_term>Fluprednisolone</mesh_term>
	<criteria>Patients endogenous anterior uveitis ( include panuveitis ) Patients 20 anterior chamber cell within one field aqueous humor ( Grade 3 high clinical sign grade ) measure slitlamp microscope Patients age ≥20 year &lt; 75 year could clearly express subjective symptom ( Patients age 20 year give informed consent include study . ) Patients give write informed consent prior initiation study Patients meet inclusion criterion Patients receive systemic administration topical administration head face include instillation corticosteroid , nonsteroidal antiinflammatory drug , antiphlogistic enzyme , immunosuppressive drug colchicine within 1 week initial instillation study drug Patients glaucoma ocular hypertension ( IOP ≥21 mmHg ) Patients corneal erosion corneal ulcer Patients viral keratoconjunctival disease , tuberculos eye disease , fungal eye diseases bacterial eye diseases Patients diabetes mellitus Patients allergy corticosteroid Patients require use contact lens study period Women might pregnant Patients participate clinical study within 6 month initiation present study Patients sensitivity steroid ( Patients previously exhibit increased IOP instillation steroid ophthalmic solution ) Patients fibrins extent might affect measurement flare</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2006</verification_date>
</DOC>